Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
10.3971/j.issn.1000-8578.2023.23.0009
- VernacularTitle:碘难治性分化型甲状腺癌靶向治疗新进展
- Author:
Lisong TENG
1
;
Zehang XU
;
Weibin WANG
Author Information
1. Department of Surgical Oncology, The First Affiliated Hospital of Medical School, Zhejiang University, Hangzhou 310003, China
- Publication Type:Research Article
- Keywords:
Radioiodine-refractory differentiated thyroid cancer;
Targeted therapy;
Tyrosine kinase inhibitor
- From:
Cancer Research on Prevention and Treatment
2023;50(5):452-457
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy has brought revolutionary breakthroughs for radioiodine-refractory differentiated thyroid cancer. New targeted drugs have prolonged the survival of patients with advanced differentiated thyroid cancer. Multiple tyrosine kinase inhibitors, represented by sorafenib and lenvatinib, have remarkably improved the progression-free survival of patients. Novel tyrosine kinase inhibitors targeting BRAF and RET mutation have also achieved remarkable curative effects, greatly enriching the treatment methods for thyroid cancer. This article reviews the latest research progress on targeted therapy in radioiodine-refractory differentiated thyroid cancer.
